Categories Annual ReportsCorporate GovernanceDefault CalendarFeatured DocumentsPresentationsProxy Statements Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Title Supernus Pharmaceuticals Advances SPN812 into Phase IIa U.S. Clinical Trial for ADHD Supernus Announces Positive Results from Phase IIa Clinical Trial for SPN 810 in Children with ADHD and Serious Conduct Problems Supernus Pharmaceuticals Closes Second Non-Dilutive Financing Supernus Pharmaceuticals Initiates Phase IIa Clinical Trial for SPN810 in Conduct Disorder Supernus Pharmaceuticals Initiates Phase III Clinical Trial for SPN-804 in Refractory Partial Onset Epileptic Seizures Supernus Pharmaceuticals Completes $75 Million Non-Recourse Note Offering Secured by Oracea<sup>®</sup> and Sanctura<sup>®</sup> XR Royalties Indevus Announces Allergan as New Partner for Sanctura<font size="-1"><sup>®</sup></font> Brand Indevus Announces FDA Approval of Sanctura® XR 649737.pdf 649738.pdf Pagination First page « first Previous page ‹ previous … Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Current page 22 Page 23 Next page next › Last page last »